Humanfu Pharmaceutical: Hydrochloride morphine ketone slow -release tablets are applied for production

On July 17, 2022, A -share company Renfu Pharmaceutical (600079.SH) hydrogen hydrochloride mild release tablets were approved for acceptance.

The company's holding subsidiary Yichang Renfang Renfu Pharmaceutical Co., Ltd. (hereinafter referred to as "Yichang Renfu", the company holds 80%of its equity) has recently received the "Acceptance Notice" for the application of hydrochloride mild release tablets.

Hydrochloride morphine is mainly used for analgesic. At present, only Yichang Renfu -Fifty -Tongyan injections are approved to be listed. In 2021, the sales of hydrogen ketone injection in Yichang people are about RMB. 400 million yuan. As of now, Yichang Renfang's project has invested approximately RMB 45 million.

Humanfu Pharmaceutical said that the application of hydrochloride morphone ketone slow -release tablets has been accepted, marking that the registered production of drugs in the variety has entered the review stage. Enriching the company's product line is conducive to improving the company's market competitiveness.

At the same time, the company reminded that the preliminary research and development of pharmaceutical products and the long and many links from the approval of products from the development and clinical trials to the production of products, and are easily affected by some uncertain factors.

- END -